Patents Assigned to Bristol-Myers Squibb Co.
  • Quinoline inhibitors of cGMP phosphodiesterase
    Patent number: 6576644
    Abstract: Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: June 10, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Method for preventing or treating pain by administering an endothelin antagonist
    Patent number: 6573285
    Abstract: Prevention or treatment of pain by administration of an endothelin antagonist.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: June 3, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventor: David E. Lebwohl
  • Process for the preparation of N-(substituted phenyl)-3-alkyl-,aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds
    Patent number: 6562994
    Abstract: The present invention provides an improved process for the preparation of N-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds of formula I that exhibit antiandrogenic activity and are useful in the treatment of malignant or benign prostatic disease or of androgen dependent disease conditions such as acne, hirsutism or seborrhea.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: May 13, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Bang-Chi Chen, Joseph E. Sundeen, Rulin Zhao
  • Artificial proteoglycans
    Patent number: 6559287
    Abstract: Novel articifial proteoglycans containing a GAG assembly site and a control sequence required for assembly, method for enhancing the biological activity of a glycosaminoglycan binding protein using artificial proteoglycans, DNA constructs of artificial proteoglycans. The artificial proteoglycans of the present invention are useful for preparations of adjuvants for vaccination, for targeting of chemokines to non-immunogenic tumor cells to enhance cellular anti-tumor response, for preparations designed to help promote wound healing, and for treatment of immunological disorders,including rheumatoid arthritis, asthma, chronic obstructive pulmonary disorder, Lupus, inflammatory bowel disease, psoriasis, osteoarthritis, and HIV infection.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: May 6, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Kelly L. Bennett, Edith A. Wolff, Alejandro A. Aruffo, Brad W. Greenfield
  • 2,3-Olefinic epothilone derivatives
    Publication number: 20030060623
    Abstract: The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor.
    Type: Application
    Filed: September 13, 2002
    Publication date: March 27, 2003
    Applicant: Bristol-Myers Squibb Co.
    Inventors: Gregory D. Vite, Robert M. Borzilleri, Gerhard Hofle, Thomas Leibold
  • Glutaryl cephalosporin amidase from Pseudomonas diminuta BS-203
    Patent number: 6528300
    Abstract: The invention provides a glutaryl 7-ACA amidase from Pseudomonas diminuta strain BS-203, which catalyzes the hydrolysis of 7-&bgr;-(4-carboxybutanamido)-cephalosporanic acid to 7-aminocephalosporanic acid and glutaric acid. The invention also provides nucleic acid sequences, vectors, and host cells useful in the production of this amidase. The glutaryl 7-ACA amidase can be used for the preparation of 7-aminocephalosporanic acid.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: March 4, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Ross Binder, Joanne L. Brown, Thomas J. Franceschini, William V. Burnett, Michael Politino, Suo Win Liu, Sean M. Tonzi
  • Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
    Patent number: 6518292
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xa is heteroaryl, preferably,  and R1, R1a, R6, Y, Xb, A, B, Z, R3, R4, R4a, R5 and R5a are as defined herein.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: February 11, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, James J. Li, Jun Li, Stephen G. Swartz
  • Enzymatic oxidative deamination process
    Patent number: 6515170
    Abstract: The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: February 4, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Ramesh N. Patel, Amit Banerjee, Venkata B. Nanduri, Steven L. Goldberg, Robert M. Johnston, Thomas P. Tully, Laszlo J. Szarka, Shankar Swaminathan, John J. Venit, Jerome L. Moniot, William J. Winter, Neal G. Anderson, David A. Lust, Gerard Crispino, Sushil K. Srivastava
  • Lactam inhibitors of FXa and method
    Patent number: 6511973
    Abstract: Compound of the formula are inhibitors of the enzyme Factor Xa. These compounds are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: January 28, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Philip D. Stein, Yan Shi, Stephen P. O'Connor, Chi Li
  • Substituted alkylketo compounds and process
    Patent number: 6486331
    Abstract: Substituted alkylketo compounds of the formula can be converted to the corresponding amino acid by a stereoselective enzymatic process. The resulting amino acid compounds can be employed as starting materials for pharmaceutically active compounds. This invention is directed to the substituted alkylketo compounds and their method of preparation.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: November 26, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Ronald L. Hanson, Paul A. Jass, Wen-Sen Li, Ramesh Patel, Keith Ramig, John J. Venit
  • Recrystallization processes
    Patent number: 6486315
    Abstract: Mercaptoalkanoylamino lactam acids are recrystallized by treatment with an agent that minimizes the formation of disulfides. Suitable agents are bismercaptans, phosphine or phosphite reducing agents, zinc metal powder, and sodium hydrosulfite.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: November 26, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: David R. Kronenthal, Rajendra P. Deshpande, James Simpson
  • Biphasic controlled release delivery system for high solubility pharmaceuticals and method
    Patent number: 6475521
    Abstract: A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: November 5, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Peter Timmins, Andrew B. Dennis, Kiren A. Vyas
  • Deprotection processes
    Patent number: 6444810
    Abstract: Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions by including an agent which minimizes the amount of disulfides. Suitable agents are bismercaptans, phosphine or phosphate reducing agents, zinc metal powder, and sodium hydrosulfite.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: September 3, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: David R. Kronenthal, Rajendra P. Deshpande
  • Transcriptional intermediary factor-2
    Publication number: 20020106727
    Abstract: The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation finction AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.
    Type: Application
    Filed: April 26, 2001
    Publication date: August 8, 2002
    Applicant: Bristol-Myers Squibb Co.
    Inventors: Pierre Chambon, Hinrich Gronemeyer, Johannes Voegel, Yves Lutz
  • Mutant penicillin G acylases
    Patent number: 6403356
    Abstract: New mutant penicillin G acylases preferably from E. coli are provided, exhibiting altered enzymatic activity. These penicillin G acylases are obtained by expression of a gene encoding said penicillin G acylase having an amino acid sequence which differs at least in one amino acid from the wild-type penicillin G acylase.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: June 11, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Li You, John James Usher, Brenda Joyce White, Jiri Novotny
  • Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
    Patent number: 6399773
    Abstract: The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH mediated diseases, such as transplant rejection and autoimmune diseases.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Chunjian Liu, T. G. Murali Dhar, Henry H. Gu, Edwin J. Iwanowicz, Katerina Leftheris, William J. Pitts
  • Benzoazepines and analogs thereof useful as growth hormone secretagogues
    Patent number: 6380184
    Abstract: Benzoazepines of the following formula wherein R1, R1a, R2, R9k, L, Q, X, Y and Z are as described herein, and analogs thereof are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: April 30, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventor: James J. Li
  • Deprotection and recrystallization processes
    Patent number: 6340752
    Abstract: Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions by including an agent which minimizes the amount of disulfides. Suitable agents are bismercaptans, phosphine or phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents are also employed in the recrystallization and reprocessing of the mercaptoalkanoylamino lactam acids.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: January 22, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: David R. Kronenthal, Theodor Denzel, Bang-Chi Chen, James H. Simpson, Rajendra P. Deshpande
  • Beta lactam compounds and their use as inhibitors of tryptase
    Patent number: 6335324
    Abstract: Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: January 1, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Gregory S. Bisacchi, William A. Slusarchyk, Uwe Treuner, James C. Sutton, Robert Zahler, Steven Seiler, David R. Kronenthal, Michael E. Randazzo, Mark D. Schwinden, Zhongmin Xu, Zhongping Shi
  • Preparation of (S)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes
    Patent number: 6329542
    Abstract: The glycinamide of the formula is reacted with the dioxolane of the formula wherein L is a leaving group such as iodo, bromo, alkylsulfonyloxy, or arylsulfonyloxy to give the dioxolane of the formula Treating the dioxolane of formula III under aqueous refluxing conditions followed by exchanging the dioxolane acetal with a dimethoxy acetal and introduction of the methyl ester gives (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester which is an intermediate in the preparation of the dual inhibitor [4S-[4&agr;(R*),7&agr;,10a&bgr;]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)-amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid. Also disclosed are storage stable salts of (S)-2-amino-6, 6-dimethoxyhexanoic acid, methyl ester.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: December 11, 2001
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Jollie D. Godfrey, Jr., David R. Kronenthal, Mark D. Schwinden, Sushil K. Srivastava, Keith Ramig, John J. Venit, Paul A. Jass, Saibaba Racha, John L. Dillon, Jr., Nachimuthu Soundararajan, Gerald L. Powers, Atul S. Kotnis